FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 7% at one stage on Monday, their biggest decline in nearly a ...

Roche's shares dropped more than 5% on Monday as the ​Swiss drugmaker failed to show that its promising breast cancer drug ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic ...

Public health specialist, Dr Marcia Johnson-Campbell, is encouraging Jamaican women who have been diagnosed with breast cancer to seek support and follow through with timely treatment, to ensure the ...

The signs and symptoms of throat cancer have been explained, with many unaware of its link to oral sex. Actor Michael Douglas went public with his cancer diagnosis back in 2010, but only revealed that ...

AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

Bishnoi Dental Care has conducted 1,000+ outreach camps in Rajasthan, screening 40,000 rural patients and improving dental ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

The biopharmaceutical company on Monday said its proposed drug, oral mezigdomide, used in combination with an existing treatment, carfilzomib and dexamethasone, demonstrated "statistically significant ...

The phase 3 SUCCESSOR-2 trial shows mezigdomide-based therapy improves PFS in R/R multiple myeloma patients previously exposed to lenalidomide.